Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 8,608 matching trials from the live ClinicalTrials.gov search.

Filters: Indianapolis, Indiana Clear all

Conditions: Colonic Neoplasms
Interventions: Control, Quantitative, Default; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 50 Years to 75 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 1 Diabetes Mellitus With Hypoglycemia
Interventions: Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg; Drug
Lead sponsor: Zucara Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 38
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 34 more

Conditions: Breast Neoplasms
Interventions: SU011248, Paclitaxel; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 6
States / cities: Harvey, Illinois • Indianapolis, Indiana • Munster, Indiana + 1 more

Conditions: Childhood Malignant Neoplasm
Interventions: Cognitive Assessment, Quality-of-Life Assessment; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Month and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 163
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 119 more

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: radiation therapy; Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 20 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 127
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 109 more

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: gefitinib; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 50
States / cities: Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 43 more

Conditions: Delirium, Cognitive Impairment, Post-traumatic Stress Disorder, Depression, Anxiety
Interventions: Haloperidol, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Solid Tumors
Interventions: Tomivosertib (eFT-508); Drug
Lead sponsor: Effector Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Tucson, Arizona • Long Beach, California • Los Angeles, California + 15 more

Conditions: Stroke, Traumatic Brain Injury
Interventions: ANSWERS - Acquiring New Skills While Enhancing Remaining Strengths, Control; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Indianapolis, Indiana • Houston, Texas

Conditions: Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions
Interventions: Denosumab, Zoledronic acid, Placebo to Denosumab, Placebo to zoledronic acid, Denosumab (for the open-label treatment phase); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 1,718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 79
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 67 more

Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Avelumab, Talazoparib, Talazoparib Tosylate; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 325
States / cities: Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 257 more

Conditions: Myasthenia Gravis
Interventions: thymectomy plus prednisone, prednisone alone; Procedure · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: Amblyopia
Interventions: 4-hour AmblyZ glasses, 12-hour AmblyZ glasses, 2-hour patching, 6-hour patching; Device
Lead sponsor: Indiana University; Other
Eligibility: 3 Years to 8 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Allergic Rhinitis
Interventions: BDP Nasal Aerosol, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 63
States / cities: Hot Springs, Arkansas • Costa Mesa, California • Downey, California + 50 more

Conditions: Hypercholesterolemia, Familial Hypercholesterolemia
Interventions: Enclitide Chloride, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 20
States / cities: Beverly Hills, California • Sacramento, California • Santa Ana, California + 17 more

Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 30 Years
Enrollment: 3,154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 208
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more

Conditions: Obstructive Sleep Apnea
Interventions: CHICA OSA, Snoring Identification Only; Other
Lead sponsor: Indiana University; Other
Eligibility: 1 Year to 11 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Peglispro, Insulin Glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Birmingham, Alabama • Zephyrhills, Florida • Indianapolis, Indiana + 7 more

Conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions: Stereotactic Body Radiation Therapy (SBRT), FOLFIRINOX; Radiation · Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Acute Lymphoblastic Leukemia
Interventions: Behavioral Intervention, Compliance Monitoring, Laboratory Biomarker Analysis, Mercaptopurine, Questionnaire Administration, Standard Follow-Up Care; Behavioral · Other · Drug + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 100
States / cities: Birmingham, Alabama • Downey, California • Duarte, California + 76 more

Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Interventions: ABBV-RGX-314, Ranibizumab (LUCENTIS®); Genetic · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 89
States / cities: Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more

Conditions: Pancreatic Cystadenoma
Interventions: Ethanol injection into a cyst; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions: parsaclisinib, placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Whittier, California • Miami, Florida + 6 more

Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Interventions: 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate; Radiation · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 211
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more

Search by objective public record fields.

Trial of a Computer-Based Presentation of Quantitative Information About Colorectal Cancer Screening

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

Radiation Therapy in Treating Young Patients With Gliomas

Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Informal Caregivers ANSWERS-VA

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy

Comparison of AmblyzTM Glasses and Patching for Amblyopia

Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Evidence-based Diagnosis and Management of Pediatric Obstructive Sleep Apnea in Primary Care

A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus

Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

EUS-Guided Pancreatic Injection of Cyst (EPIC) Trial

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)